after the date of enrollment of the last patient, we investigated survival status of each patient and identified a group with recurrence. Results: Among 107 patients, 29 patients developed recurrence with a mean follow-up of 18.1 months (range 14 to 21). P-stage was significantly more advanced in the recurrence group than in the non-recurrence group (p = 0.005). Serum IL-6 levels on POD 1 were significantly higher in the recurrence group than in the non-recurrence group (p = 0.007). In Cox's proportional hazards regression, P-stage and serum IL-6 levels on POD 1 were significant independent predicting factors for postoperative early recurrence (p = 0.006, p = 0.003). Conclusions: The higher the serum IL-6 levels on POD 1, the higher the risk of early postoperative recurrence, even when curative pulmonary resection can be accomplished in lung cancer patients.
Introduction
Lung cancer is the leading cause of cancer-related deaths in the world. 1) Almost 90% 2) of resected lung cancer patients have non-small cell lung cancer (NSCLC) and a poor prognosis because the 5-year survival rate for resected NSCLC patients with pathological (p-) stage I A is 67 to 79.5%. 2, 3) Therefore, we can suggest that the risk of recurrence in NSCLC patients is high, even when they are operated on while they have early stage lung cancer. One possible cause of poor survival is that an extensive rise of the inflammatory cytokine levels, induced by surgical stress, may create a more favorable environment for the growth of tumor cells. 4) This postoperative increased inflammatory cytokine acts as growth factors or reduces antiangiogenic factors. Consequently, it may become a risk factor of recurrence. 5, 6) However, there have been no clinical reports on lung cancer patients reviewing from this point of view so far. In this study, we examined whether inflammatory cytokine levels in patients who underwent curative lung cancer surgery affected postoperative early recurrence.
Materials and Methods
From November 2007 to June 2008, we prospectively enrolled 116 NSCLC patients who underwent pulmonary resections at 4 hospitals, including Kyorin University hospital (n = 36), Fukujuji hospital (n = 51), Sagamiharakyoudou hospital (n = 15) and Nagaoka Central General hospital (n = 14), for the analysis of pre-and post-operative inflammatory cytokine levels. The study was approved by the institutional review board on human research at each hospital. Informed consent was obtained from each patient.
Among the 116 patients, we excluded 9 patients who turned out to undergo non-curative pulmonary resections, including 2 patients with pleural disseminations, 3 with pathologically positive bronchial stumps for cancer, 2 with surgically unresectable for metastatic lymphnodes, and 2 with pathologically positive chest wall stumps for cancer. The remaining 107 patients undergoing curative pulmonary resections for NSCLC were the subjects of this study. For preoperative assessment, in all patients, chest and upper abdomen computed tomography (CT), bone scintigram or positron emission tomography-CT and brain magnetic resonance imaging were taken to rule out distant metastases. In all patients, histological diagnosis of NSCLC was made preoperatively or intraoperatively. All patients were staged according to the 5th edition of the UICC-TNM staging system, which was published in 1997. 7) Serum Interleukin-6 (IL-6) was measured preoperatively, and on postoperative day (POD) 0, 1, and 2. Blood samples for the measurement of IL-6 were obtained one hour after completion of the operation on POD 0 and on the morning of POD 1 and 2. The samples were centrifuged at 3000 G for 5 minutes, and then were stored at -80°C until the measurement of serum IL-6 was performed. Serum IL-6 levels were measured using Chemiluminescent Enzyme Immunoassay (CLEIA).
Curative pulmonary resections in this study included lobectomy under video-assisted thoracoscopic surgery (VATS) and lobectomy under thoracotomy (TH). The choice of VATS or TH was up to each surgeon. VATS lobectomy was performed as follows. A 5 to 8-cm long skin incision was made at the fourth or fifth intercostal space in the anterolateral chest or in the auscultation triangle, serving as a utility mini-thoracotomy. One to three working ports were placed for the insertion of thoracoscopic instruments. Neither muscles (latissimus dorsi muscle or serratus anterior muscle) nor ribs were cut. Not a metal rib spreader but a soft silicon rubber instrument (ALEXIS ® WOUND RETRACTOR SYSTEMS) was applied to the mini-thoracotomy wound. Lobectomy under thoracotomy was defined as the following, the procedure with an over 8-cm long skin incision, with the use of a metal rib spreader for the thoracotomy wound, or with the division of either ribs or extrathoracic muscles (the latissimus dorsi or the serratus anterior). Concerning lymphadenectomy, this study included those patients who underwent lobectomy with mediastinal lymphadenectomy as well as those who did lobectomy without it.
Between July 2009 and August 2009, 1 year after the date of enrollment of the last patient, we investigated survival status of each patient, and identified patients with recurrence.
Serum IL-6 levels, clinical data and operative data are presented as mean ± standard error (range). A two-tailed t test and Chi-square test for independence were used for the comparison of clinical data. A one-way analysis of variance for repeated measures was used for the comparison of serum IL-6 levels at each time point. Disease free survival time was defined as duration between the date of surgery and the last follow-up date or the recurrent date. Disease free survival curves were estimated by the Kaplan-Meier method, and the difference in disease free survival was tested by the log-rank test. The influence of variables on the disease free survival was also analyzed by the Cox's proportional hazards regression. Probability values less than 0.05 were considered statistically significant. Statistical analysis was performed with SPSS 12.0J for Windows.
Results
Comparisons of the non-recurrence group and the recurrence group are shown in Table 1 . Age, gender and histological type were not significantly different between the non-recurrence group and the recurrence group. P-stage was significantly more advanced in the recurrence group compared with the non-recurrence group (p = 0.005). The ratios of VATS to TH were significantly higher in the non-recurrence group compared with the recurrence group (p = 0.019). The ratios of procedures with mediastinal lymphadenectomy to those without it were not significantly different between the two groups. Quantity of hemorrhage and operating time were significantly different between the non-recurrence group and the recurrence group (p = 0.030, p = 0.012; respectively).
The levels of preoperative and postoperative serum IL-6 in the non-recurrence group and the recurrence group are shown in Table 1 . Serum IL-6 levels on POD 1 were significantly higher in the recurrence group than in the non-recurrence group (p = 0.007). Preoperative serum IL-6 levels and serum IL-6 levels on POD 0 and POD 2 were not significantly different between the two groups. Taking into account the influence of pathological stage, we analyzed the levels of serum IL-6 for the non-recurrence group and those for the recurrence group according to pathological stage ( Fig. 1) . Preoperative serum IL-6 levels and serum IL-6 levels on POD 1 were significantly higher in the recurrence group than in the non-recurrence group for patients with confirmed pathological stage I A + I B (p = 0.011, 0.043; respectively) (Fig. 1A) . Serum IL-6 levels on POD 0 and POD 2 were not significantly different between the two groups (Fig. 1A) . Preoperative serum IL-6 levels and serum IL-6 levels on POD 0, POD 1 and POD 2 were not significantly difference between the two groups for patients with confirmed pathological stage II + III (Fig. 1B) .
The levels of preoperative and postoperative serum IL-6 in the VATS group and the TH group are shown in Fig. 2 . Serum IL-6 levels on POD 0, 1, and 2 were significantly higher in the TH group than in the VATS group for all patients of this study (p = 0.003, 0.002, 0.001; respectively) ( Fig. 2A) . Preoperative serum IL-6 levels were not significantly different between the two groups ( Fig. 2A) . Serum IL-6 levels on POD 0, 1, and 2 were significantly higher in the TH group than in the VATS group for patients with confirmed pathological stage I A + I B (p = 0.012, 0.003, 0.002; respectively) (Fig. 2B) . Preoperative serum IL-6 levels were not significantly different between the two groups (Fig. 2B) . The levels of preoperative and postoperative serum IL-6 were not significantly different between the two groups for patients with confirmed pathological stage II + III.
The overall disease free survival curve is shown in Fig. 3 . The mean disease free interval for all patients was 18.1 ± 0.3 months (95% CI: 17.4-18.7). Overall disease free survival rate was 69.3%. The 1-year disease free survival rate was 81.7%. No patient died from causes other than cancer related causes during the follow-up period of this study.
Disease free survival curves, according to pathological stage, are shown in Fig. 4 . Overall disease free survival rates were 87.1% for I A, 69.9% for I B, 33.3% for II A, 50.0% for II B, 44.4% for III A and 44.4% for III B. The 1-year disease free survival rates were 100% for I A, 81.1% for I B, 66.7% for II A, 75.0% for II B, 55.6% for III A and 83.3% for III B. There were significant differences in overall disease free survival among the six pathological stage groups (p = 0.003). The sites of recurrence are shown in Table 2 . At the time of diagnosis of the first tumor recurrence, 22 (75.9%) patients had a single focal recurrent disease, and the remaining 7 (24.1%) patients had multifocal recurrent diseases. All patients with confirmed pathological stage I A + I B had a single focal disease. The most common sites were lung (n = 9, 31.0%), followed by mediastinal lymphnode (n = 8, 27.5%), bone (n = 7, 24.1%), and brain (n = 7, 24.1%). The ratios of patients with local recurrence were significantly higher for patients with confirmed pathological stage III A + III B (75.0%) than for patients with confirmed pathological stage I A + I B (14.3%) or II A + II B (28.6%) (p = 0.015). Contrarily, the ratios of patients with distant recurrence were not significantly different among the three groups (I A + I B: 85.7%, II A + II B: 85.7%, III A + III B: 75.0%) (p = 0.792). There was no patient with recurrence at the resected stumps.
Cox's proportional hazards regression analyses of all factors (Age, Gender, p-stage, VATS or TH, MLA -or +, quantity of hemorrhage, operating time, and serum IL-6 levels preoperatively and on POD 0, 1, 2) are shown in Table 1 . P-stage and serum IL-6 levels on POD 1 were significant, independent predisposing factors for the development of postoperative early recurrence (p = 0.005, p = 0.003; respectively). Age, Gender, VATS or TH, MLA -or +, quantity of hemorrhage, operating time, and serum IL-6 levels preoperatively and on POD 0, 2 were not significant independent predisposing factors for the development of postoperative early recurrence.
Discussion
Studies using rats demonstrate that surgery is effective in removing the pr ima r y lesion and metastatic lymphnodes but also may accelerate the development of pre-existing micrometastasis or promote the establishment of new metastasis. 8, 9) Based on these findings, a similar possibility can be applied to lung cancer surgery for humans. Relapse occurred within one year after pulmonary resections in approximately 50% of patients who had recurrence within 5 years after surgery for the treatment of NSCLC.
10) The risk of early recurrence in patients with resected NSCLC is, therefore, suggested being high. In this study, to examine the influence of surgery on cancer progression, we investigated the correlation between postoperative serum IL-6 levels and postoperative early recurrence.
Serum IL-6 levels reflect IL-6 levels in the tumor component. 11, 12) And several tumor cell lines produce IL-6. 13, 14) In addition the IL-6 levels are kept high in eternity by the IL-6-IL-6 receptor autocrine loop, which has been found to exist in several tumors. 15, 16) These findings suggest that the transient rise of serum IL-6 levels leads to keep IL-6 levels high in the tumor component. IL-6 produced by the tumor cells protects themselves against the antitumor immune response 17) and induces proliferation or prolongation of survival in the tumor cells. [18] [19] [20] Recently, in molecular biological theory, the mechanisms that the inflammatory cytokines gives to tumors have been elucidated. In colorectal cancers, IL-6-IL-1ra network system is associated with the allelic loss of a portion of chromosome 18q, reflecting the genetic alteration of tumor suppressor genes. 21) This finding suggests that since an extensive rise of IL-6 levels in the tumor component leads to mutate the alleles in molecular components, tumor cells may continue to activate the growth of tumors in eternity.
The present study demonstrated that p-stage and serum IL-6 levels on POD 1 were significant, independent predisposing factors for the development of postoperative early recurrence. Undoubtedly, patients in the recurrence group should have lung cancer with more advanced pathological stages. Never the less, when we did multivariate analysis, both serum IL-6 levels on POD 1 and p-stage were found to be independent predisposing factors for postoperative early recurrence. Therefore, we assume that the transient rise of postoperative serum IL-6 levels may increase the risk of postoperative early recurrence independently. On the other hand, preoperative serum IL-6 levels and serum IL-6 levels on POD 0 and POD2 were not found to be independent predisposing factors for postoperative early recurrence. We speculate the following possible reasons for these mysterious phenomena.
In this study, serum IL-6 levels were low preoperatively and were increased on POD 0 both in the recurrence group and the non-recurrence group. Thereafter, serum IL-6 levels were decreased from their highest levels on POD 0 to their lowest levels on POD2 in both groups of patients. About the preoperative serum IL-6 levels, NSCLC patients whose serum IL-6 levels have increased before treatments may have a poor prognosis. 22, 23) However, this study included no patients with advanced cancer whose serum IL-6 levels increased by tumors themselves. About the serum IL-6 levels on POD 0, serum IL-6 levels peaked between 6 and 12 hours after the incision or between 3 hours and 1 day after the skin closure. 24, 25) Therefore, serum IL-6 levels might not be enough increased one hour after the completion of operation. About the serum IL-6 levels on POD 2, since this study neither included the patient who died of complications nor the patient who contracted a disease in serious complications, serum IL-6 levels decreased on POD 2 for most patients.
When we took into account the influence of pathological stages, we discovered interesting findings. Only for patients with confirmed pathological stage I A + I B, preoperative serum IL-6 levels were significantly higher in the recurrence group than in the non-recurrence group. In addition, only for patients with confirmed pathological stage I A + I B, serum IL-6 levels on POD 1 were significantly higher in the recurrence group than in the nonrecurrence group. It might to be due to the fact that the number of patients with confirmed pathological stage II + III was too small to elucidate the statistically significant differences. Therefore, we might need larger sample size.
The serum IL-6 levels have known to be affected by the approach, i.e. VATS or thoracotomy. Previous studies [26] [27] [28] comparing serum IL-6 levels in VATS with those in conventional thoracotomy demonstrated that the serum IL-6 levels were significantly lower in VATS than in conventional thoracotomy. Our results for all patients or for patients with confirmed pathological stage I A + I B were consistent with those in previously published reports. However, the serum IL-6 levels for patients with confirmed clinical stage II + III were not significantly lower in VATS than in TH. It might be due to the fact that the number of patients with confirmed clinical stage II + III who underwent VATS was small. Consequently, the difference in the approach (VATS versus TH) was not significant, independent predisposing factors for the development of postoperative early recurrence.
Finally, the incidence of the distant recurrence was not significantly related to the progression of pathological stages in patients with recurrence. Contrarily, patients with more advanced pathological stages had a higher incidence of the local recurrence.
In conclusion, the higher the serum IL-6 levels on POD 1, the higher the risk of postoperative early recurrence, even when curative pulmonary resection can be accomplished in lung cancer patients. When we select surgical treatment for patients with lung cancer, we should consider that surgery itself may carry the risk of postoperative early recurrence. For a reduction in the postoperative transient rise of serum IL-6 levels, a minimally invasive approach might be the solution.
